Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

Feb 4, 2025 · Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external ...

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.

At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. We have a deep and diverse pipeline of cutting-edge therapeutic approaches that aim to improve outcomes.

Live. Win. Thrive. We dare to ask questions that lead to lifesaving treatments. Join us in pushing the boundaries of biotechnology in a career at Amgen.

Amgen harnesses the best of biotechnology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative human therapeutics.

For reimbursement options and information on help paying for Amgen medications in the U.S., please visit amgensupportplus.com for more information.

Amgen is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Latest Press Releases

THOUSAND OAKS, Calif., Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway ...

Amgen Inc.